Cargando…

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

BACKGROUND: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishino, Mizuki, Ramaiya, Nikhil H., Chambers, Emily S., Adeni, Anika E., Hatabu, Hiroto, Jänne, Pasi A., Hodi, F. Stephen, Awad, Mark M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168591/ https://www.ncbi.nlm.nih.gov/pubmed/28018599 http://dx.doi.org/10.1186/s40425-016-0193-2

Ejemplares similares

Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications
por: Park, Hyesun, et al.
Publicado: (2023)

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
por: Nishino, Mizuki, et al.
Publicado: (2014)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
por: Nishino, Mizuki, et al.
Publicado: (2020)

Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics
por: Nishino, Mizuki, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2017)

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
por: Awad, Mark M., et al.
Publicado: (2017)

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome
por: Araki, Tetsuro, et al.
Publicado: (2019)

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
por: Nishino, Mizuki, et al.
Publicado: (2012)

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations
por: Ogino, Atsuko, et al.
Publicado: (2020)

Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study
por: Hida, Tomoyuki, et al.
Publicado: (2021)

Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality
por: Kubo, Takeshi, et al.
Publicado: (2016)

Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterization—iLEAD study()
por: Kubo, Takeshi, et al.
Publicado: (2016)

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
por: Schoenfeld, Jonathan D., et al.
Publicado: (2019)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome
por: Park, Hyesun, et al.
Publicado: (2019)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Anterior mediastinal masses in the Framingham Heart Study: Prevalence and CT image characteristics
por: Araki, Tetsuro, et al.
Publicado: (2015)

Special Issue: Chest Imaging 2021
por: Hatabu, Hiroto
Publicado: (2020)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Park, Eun-Joo, et al.
Publicado: (2022)

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023)

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Intrathoracic malignant peripheral nerve sheath tumors: imaging features and implications for management
por: Kamran, Sophia Constance, et al.
Publicado: (2013)

A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
por: Ghergurovich, Jonathan M., et al.
Publicado: (2020)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Subsolid pulmonary nodules: Controversy and perspective
por: Hammer, Mark M., et al.
Publicado: (2020)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence
por: O’Regan, Kevin, et al.
Publicado: (2013)

Projected lung areas using dynamic X-ray (DXR)
por: Hino, Takuya, et al.
Publicado: (2020)

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
por: Asano, Hiroto, et al.
Publicado: (2023)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
por: Angell, Trevor E., et al.
Publicado: (2017)

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
por: Alessi, Joao V, et al.
Publicado: (2020)

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

PD-1 Inhibitors in the Advanced Esophageal Cancer
por: Hong, Ye, et al.
Publicado: (2019)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_604jm12k1lblhg09t66ioqubcp